Friday, 16 October 2026European Markets

DOCK.PETR.AMBES AM And AKER SOLUTIONS Have A High Dividend Yield And Return On Equity In The Energy Sector.

Loading stream...

(vianews) - dock.petr.ambes am (dpam.pa) is among this list of stock assets with the highest dividend rate and return on equity on the energy sector.

financial asset price forward dividend yield return on equity
dock.petr.ambes am (dpam.pa) €484.00 6.82% 7.95%
aker solutions (akso.ol) kr46.56 2.17% 17.09%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. dock.petr.ambes am (dpam.pa)

6.82% forward dividend yield and 7.95% return on equity

les docks des pétroles d'ambès -sa engages in the storage and shipping of petroleum products in france. it stores and distributes species, diesel, and combustibles, as well as bio, jet, technical, and marine fuel products. the company was founded in 1930 and is based in carbon-blanc, france.

earnings per share

as for profitability, dock.petr.ambes am has a trailing twelve months eps of €43.24.

pe ratio

dock.petr.ambes am has a trailing twelve months price to earnings ratio of 11.19. meaning, the purchaser of the share is investing €11.19 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.95%.

volatility

dock.petr.ambes am's last week, last month's, and last quarter's current intraday variation average was 1.68%, 0.37%, and 1.90%.

dock.petr.ambes am's highest amplitude of average volatility was 1.68% (last week), 0.79% (last month), and 1.90% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, dock.petr.ambes am's stock is considered to be oversold (<=20).

more news about dock.petr.ambes am.

2. aker solutions (akso.ol)

2.17% forward dividend yield and 17.09% return on equity

aker solutions asa provides solutions, products, systems, and services to the oil and gas industry worldwide. it offers field planning, feasibility, and concept studies; specialist engineering, project management, and procurement services; floater designs, offshore wind, as well as engages in design, delivery, and construction of deep-water risers, oil, and gas production, and receiving and processing facilities. in addition, the company provides offshore fish farming, carbon capture, utilization and storage, hydrogen, and offshore wind solutions. further, the company designs and constructs jackets for construction services and offers electrification services; and designs and constructs offshore oil and gas production facilities and onshore receiving and processing facilities. additionally, the company provides subsea production, compression, pump, power distribution, and processing systems, and subsea lifecycle services. furthermore, the company offers maintenance, modifications, decommissioning, asset integrity management, hook-up, and completion solutions. aker solutions asa was founded in 1841 and is headquartered in fornebu, norway.

earnings per share

as for profitability, aker solutions has a trailing twelve months eps of kr3.41.

pe ratio

aker solutions has a trailing twelve months price to earnings ratio of 13.65. meaning, the purchaser of the share is investing kr13.65 for every norwegian krone of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.09%.

moving average

aker solutions's value is way higher than its 50-day moving average of kr39.50 and way above its 200-day moving average of kr38.75.

more news about aker solutions.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com